Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




DNA Analysis Systems Reduce DNA Input and Increase Sample Throughput

By Labmedica staff writers
Posted on 16 Jan 2008
Two new products for DNA analysis double sample throughput and reduce DNA input requirements by as much as 70%. More...
They offer enhanced signal discrimination and a new single nucleotide polymorphism (SNP) algorithm.

Launched by Illumina's (San Diego, CA, USA) microarray business, the two new products are on the Human1M-Duo beadchip and contain markers for more than one million diverse genetic variants, all of which can be used for both whole-genome genotyping and copy number variation (CNV) analysis.

In addition to Human1M single-sample BeadChip, Illumina's new Human1M-Duo features can identify disease-associated SNPs and intelligently select high-density SNPs in coding regions of the genome. The Human1M-Duo also provides the highest available power to detect SNPs associated with diseases and the least number of large gaps for the identification of CNVs.
The Infinium HD Human1M-Duo (two samples/chip) and the Human610-Quad (four samples/chip), feature up to 2.3 million single nucleotide polymorphisms (SNPs) per beadchip. First customer shipments of the Human610-Quad and Human1M-Duo beadchips are expected in the first and second quarters of 2008, respectively.

The four-sample format of the Human610-Quad beadchip provides customers with a significant increase in sample throughput and reduced handling in the lab. Built upon the content of Illumina's broadly adopted HumanHap550 beadchip, the Human610-Quad beadchip has 550,000 SNPs plus an additional 60,000 genetic markers per sample. Both the Infinium HD Human1M-Duo and Human610-Quad beadchips include high-value, CNV content developed in conjunction with deCODE genetics, only found on Illumina arrays.

"The Human1M-Duo and Human610-Quad beadchips provide our customers with significant advances, including increased sample throughput, lower input sample volume, and improvements to the Infinium assay that enhance overall system performance. Concurrent with the development of these new array products, Illumina has implemented new decoding instruments into its operations that will effectively double Illumina's array manufacturing capacity over the next several quarters,” said John Stuelpnagel, senior vice president, COO, and general manager of Illumina's Microarray Business.

Illumina's genotyping solutions offer a flexible beadchip design and high-density architecture. Infinium HD products provide a powerful complement to Illumina's genotyping offering, which includes Infinium II, iSelect Infinium, GoldenGate, and VeraCode genotyping products.


Related Links:
Illumina

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.